500 related articles for article (PubMed ID: 31493397)
1. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Feagan BG; Hibi T; Tuttle JL; Klekotka P; Friedrich S; Durante M; Morgan-Cox M; Laskowski J; Schmitz J; D'Haens GR
Gastroenterology; 2020 Feb; 158(3):537-549.e10. PubMed ID: 31493397
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.
Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Hibi T; D'Haens GR; Tuttle JL; Krueger K; Friedrich S; Durante M; Arora V; Naegeli AN; Schmitz J; Feagan BG
Clin Gastroenterol Hepatol; 2022 Jan; 20(1):105-115.e14. PubMed ID: 32950748
[TBL] [Abstract][Full Text] [Related]
3. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
[TBL] [Abstract][Full Text] [Related]
4. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
Sandborn WJ; Peyrin-Biroulet L; Zhang J; Chiorean M; Vermeire S; Lee SD; Kühbacher T; Yacyshyn B; Cabell CH; Naik SU; Klassen P; Panés J
Gastroenterology; 2020 Feb; 158(3):550-561. PubMed ID: 31711921
[TBL] [Abstract][Full Text] [Related]
6. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
Rubin DT; Dotan I; DuVall A; Bouhnik Y; Radford-Smith G; Higgins PDR; Mishkin DS; Arrisi P; Scalori A; Oh YS; Tole S; Chai A; Chamberlain-James K; Lacey S; McBride J; Panés J;
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):17-27. PubMed ID: 34798036
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease.
Sands BE; Peyrin-Biroulet L; Kierkus J; Higgins PDR; Fischer M; Jairath V; Hirai F; D'Haens G; Belin RM; Miller D; Gomez-Valderas E; Naegeli AN; Tuttle JL; Pollack PF; Sandborn WJ
Gastroenterology; 2022 Feb; 162(2):495-508. PubMed ID: 34748774
[TBL] [Abstract][Full Text] [Related]
8. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038
[TBL] [Abstract][Full Text] [Related]
9. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G; Dubinsky M; Kobayashi T; Irving PM; Howaldt S; Pokrotnieks J; Krueger K; Laskowski J; Li X; Lissoos T; Milata J; Morris N; Arora V; Milch C; Sandborn W; Sands BE;
N Engl J Med; 2023 Jun; 388(26):2444-2455. PubMed ID: 37379135
[TBL] [Abstract][Full Text] [Related]
10. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W
Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.
Sandborn WJ; Baert F; Danese S; Krznarić Ž; Kobayashi T; Yao X; Chen J; Rosario M; Bhatia S; Kisfalvi K; D'Haens G; Vermeire S
Gastroenterology; 2020 Feb; 158(3):562-572.e12. PubMed ID: 31470005
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.
Papp K; Warren RB; Green L; Reich K; Langley RG; Paul C; Asahina A; Johnson L; Arora V; Osuntokun O; Lebwohl M
Lancet Rheumatol; 2023 Sep; 5(9):e542-e552. PubMed ID: 38251498
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study.
Reich K; Rich P; Maari C; Bissonnette R; Leonardi C; Menter A; Igarashi A; Klekotka P; Patel D; Li J; Tuttle J; Morgan-Cox M; Edson-Heredia E; Friedrich S; Papp K;
Br J Dermatol; 2019 Jul; 181(1):88-95. PubMed ID: 30734266
[TBL] [Abstract][Full Text] [Related]
14. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.
Carbonnel F; Colombel JF; Filippi J; Katsanos KH; Peyrin-Biroulet L; Allez M; Nachury M; Novacek G; Danese S; Abitbol V; Bossa F; Moreau J; Bommelaer G; Bourreille A; Fumery M; Roblin X; Reinisch W; Bouhnik Y; Brixi H; Seksik P; Malamut G; Färkkilä M; Coulibaly B; Dewit O; Louis E; Deplanque D; Michetti P; Sarter H; Laharie D; ;
Gastroenterology; 2016 Feb; 150(2):380-8.e4. PubMed ID: 26632520
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
Blauvelt A; Kimball AB; Augustin M; Okubo Y; Witte MM; Capriles CR; Sontag A; Arora V; Osuntokun O; Strober B
Br J Dermatol; 2022 Dec; 187(6):866-877. PubMed ID: 35791755
[TBL] [Abstract][Full Text] [Related]
18. Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis.
Dubinsky MC; Jairath V; Feagan BG; Naegeli AN; Tuttle J; Morris N; Shan M; Arora V; Lissoos T; Agada N; Hibi T; Sands BE
BMJ Open Gastroenterol; 2023 Mar; 10(1):. PubMed ID: 37001911
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis.
Naganuma M; Sugimoto S; Mitsuyama K; Kobayashi T; Yoshimura N; Ohi H; Tanaka S; Andoh A; Ohmiya N; Saigusa K; Yamamoto T; Morohoshi Y; Ichikawa H; Matsuoka K; Hisamatsu T; Watanabe K; Mizuno S; Suda W; Hattori M; Fukuda S; Hirayama A; Abe T; Watanabe M; Hibi T; Suzuki Y; Kanai T;
Gastroenterology; 2018 Mar; 154(4):935-947. PubMed ID: 29174928
[TBL] [Abstract][Full Text] [Related]
20. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
Atreya R; Peyrin-Biroulet L; Klymenko A; Augustyn M; Bakulin I; Slankamenac D; Miheller P; Gasbarrini A; Hébuterne X; Arnesson K; Knittel T; Kowalski J; Neurath MF; Sandborn WJ; Reinisch W;
Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1063-1075. PubMed ID: 33031757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
